Email  |  OA

Hotline:+86 21 5285 5285  CN   |   EN

CN   |   EN

Current location:Home >> 首页焦点图

BravoVax Co., Ltd (BravoVax) was awarded the "Most Promising Vaccine Candidate in APAC" fo

Author:博沃管理员    Release time:2023-11-29 23:00:00


On November 28th, 2023, the awards ceremony for Asia Pacific Vaccine Excellence Awards 2023,organized by the internationally renowned consulting firm IMAPAC, was grandly held at the Marina Bay Sands International Convention Center in Singapore. BravoVax Co., Ltd (BravoVax) was awarded the "Most Promising Vaccine Candidate in APAC" for its outstanding performance in vaccine innovations. The “Most Promising Vaccine Candidate in APAC” was also the highest honor award in the series of awards. Dr. Wu Ke, CEO of BravoVax, was invited to give a speech at the conference, participate in panel discussions and attend this awards ceremony.


The purpose of Asia Pacific Vaccine Excellence Awards (AVEA) 2023 is to recognize the outstanding achievements of vaccine & supply chain experts, organizations, and the newest technologies in Asia. The Asia Pacific Vaccine Excellence Award applauds extraordinary leaders & trendsetters of today and inspires the innovators of tomorrow. Grand winner of the “Most Promising Vaccine Candidate in APAC” this time is a great affirmation and encouragement to the leadership and R&D innovation of the BravoVax in vaccine industry.


In the future, BravoVax will continue to deeply cultivate the vaccine field, adhere to technological innovation, and serve the health industry with the best quality, committed to becoming a pioneer in the global vaccine industry.